Filion Lionel G, Matusevicius Darius, Graziani-Bowering Gina M, Kumar Ashok, Freedman Mark S
Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada.
Clin Immunol. 2003 Feb;106(2):127-38. doi: 10.1016/s1521-6616(02)00028-1.
Multiple sclerosis has been postulated to be an autoimmune disease in which Th1 immune responses predominate. This response is associated with an increased production of IFNgamma and IL12 produced by T cells and by cells of the monocyte (MO) lineage, respectively. An increased expression of costimulatory molecules by T cells and antigen-presenting cells is also observed. We hypothesized that in relapsing-remitting MS (RRMS) (with or without of IFNbeta treatment) and in secondary progressive patients (SPMS) IL12 and costimulatory molecules (CD80 [B7-1], CD86 [B7-2], CD28, CD40, CD40L) would be differentially produced or expressed by MO or T cells. We performed cross-sectional and longitudinal flow cytometric studies (at monthly intervals) on peripheral blood mononuclear cells (PBMC) or on MO from SPMS or untreated and IFNbeta-treated patients with RRMS. We determined that CD86 and CD40L expression was highest on MO derived from SPMS patients compared to those from RRMS or from healthy controls (HC). In vitro culture of PBMC with recombinant human IL10, a cytokine that may be increased in response to treatment with IFNbeta and that down-regulates CD86 expression, reduced the expression of CD86 on MO derived from RRMS patients to a much higher degree compared to cells derived from SPMS or HC. In vitro secreted IL12 levels from freshly isolated MO from SPMS patients were more than 10-fold higher than either the treated or the untreated RRMS or HC. RRMS patients treated with IFNbeta demonstrated slightly lower levels of MO IL12 secretion. Our data suggest that a key mechanism in the pathogenesis of MS is the increased expression of CD86 and CD40L and the increased production of IL12 during disease progression. Part of the mechanism of action of IFNbeta may be to reduce MO CD86 and CD40L expression and IL12 secretion; failure to do so might signify either a lack of response or a transition to a more progressive phase of illness.
多发性硬化症被推测是一种以Th1免疫反应为主导的自身免疫性疾病。这种反应分别与T细胞和单核细胞(MO)谱系细胞产生的IFNγ和IL12增加有关。还观察到T细胞和抗原呈递细胞共刺激分子的表达增加。我们假设,在复发缓解型多发性硬化症(RRMS)(无论是否接受IFNβ治疗)以及继发进展型患者(SPMS)中,MO或T细胞会差异产生或表达IL12和共刺激分子(CD80 [B7-1]、CD86 [B7-2]、CD28、CD40、CD40L)。我们对SPMS患者以及未经治疗和接受IFNβ治疗的RRMS患者的外周血单个核细胞(PBMC)或MO进行了横断面和纵向流式细胞术研究(每月一次)。我们确定,与RRMS患者或健康对照(HC)相比,SPMS患者来源的MO上CD86和CD40L表达最高。用重组人IL10(一种可能因IFNβ治疗而增加且下调CD86表达的细胞因子)对PBMC进行体外培养,与SPMS或HC来源的细胞相比,RRMS患者来源的MO上CD86的表达降低程度更高。SPMS患者新鲜分离的MO体外分泌的IL12水平比接受治疗或未接受治疗的RRMS患者或HC高出10倍以上。接受IFNβ治疗的RRMS患者MO分泌的IL12水平略低。我们的数据表明,MS发病机制中的一个关键机制是疾病进展过程中CD86和CD40L表达增加以及IL12产生增加。IFNβ的部分作用机制可能是降低MO的CD86和CD40L表达以及IL12分泌;无法做到这一点可能意味着无反应或疾病向更进展阶段的转变。